Absolute granulocyte count (AGC) >= ,/mm^, within  weeks of randomization
Absolute granulocyte count >= . x ^/mm^
Absolute granulocyte count >=  K/uL
Absolute granulocyte count >= ,/mm^ (. x ^/L)
Absolute granulocyte count >= ,/mcL, within  days of starting therapy
Absolute granulocyte count < ; platelets <,.
Absolute granulocyte count < ; platelets <,.
Marrow: Hemoglobin ?. gm/dL, absolute granulocyte count (AGC) ?,/mm platelets ?,/mm, absolute lymphocyte count ?/mm.
Peripheral absolute granulocyte count of > /mm^
A. Marrow: Hemoglobin ?. gm/dL, absolute granulocyte count (AGC) ?,/mm, platelets ?,/mm, absolute lymphocyte count ?/mm.
Absolute granulocyte count (AGC) >= ,
Absolute granulocyte count < ,/ul
Absolute granulocyte count < ,/ul
Absolute granulocyte count > . x ^/mm
Absolute granulocyte count >= . x ^/mm^
Absolute granulocyte count >= . x ^/mm^
Absolute granulocyte count (AGC) >= , cells/mm^
Absolute granulocyte count >= ,/mm^
Absolute granulocyte count > ,/mcL
Absolute granulocyte count (AGC) >= ,/mm
Marrow: Hemoglobin ?. gm/dL, absolute granulocyte count (AGC) ?,/mm, platelets ?,/mm, absolute lymphocyte count ?/mm.
Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) >=  per uL
Marrow: Hemoglobin ?. dm/dL, absolute granulocyte count (AGC)?,/mm^, platelets ?,/mm^, absolute lymphocyte count ?/mm^.
Absolute peripheral granulocyte count of >= ,/mm^
Normal organ and marrow function as defined below: Absolute granulocyte count ? ,/mm Absolute lymphocyte count ? /mm Platelets ? ,/mm Total bilirubin ? mg/dL AST(SGOT)/ALT(SGPT) <x institutional upper limit of normal Creatinine <. mg/dL
Absolute granulocyte count >= ,/mm^
Absolute granulocyte count >= /mm^
An absolute granulocyte count > /L
Absolute granulocyte count (AGC) >=  cells/mm^
Absolute granulocyte count (ANC) >= . x ^/mm^
Absolute granulocyte count >= . x ^/L
Patients should have adequate bone marrow function defined by an absolute peripheral granulocyte count of > , /mm and platelet count >,/mm along with an absence of a red blood cell transfusion in the two weeks prior to their participation in the trial
